Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.3875 AUD 0.65%
Market Cap: 111.7m AUD

EV/EBIT
Enterprise Value to EBIT

-6.6
Current
-10.8
Median
16.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-6.6
=
Enterprise Value
109.8m AUD
/
EBIT
-16.6m AUD
EBIT Growth EV/EBIT to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBIT: 1 871.2
Negative Multiple: -6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.5
13%
1.3
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
168
23%
7.3
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.3
10%
0.9
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-7.3
2-Years Forward
EV/EBIT
-3
3-Years Forward
EV/EBIT
-9.2